Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
about
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemiaT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaThe Sleeping Beauty transposon system: a non-viral vector for gene therapySuicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytesChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesStrategies for combining immunotherapy with radiation for anticancer therapyT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectCARs in chronic lymphocytic leukemia -- ready to driveFrom monoclonal antibodies to chimeric antigen receptors for the treatment of human malignanciesImmunotherapy advances for glioblastomaNovel immunotherapies for hematologic malignanciesAdoptive T-cell therapy for LeukemiaChimeric antigen receptor therapy for cancerChimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsIndividual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategyRedirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ TumorsHow (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferSafety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasOverview and recent advances in the treatment of neuroblastoma.Sleeping beauty system to redirect T-cell specificity for human applications.Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.Engineering cord blood to improve engraftment after cord blood transplant.The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptorGenetic modification of T cells redirected toward CS1 enhances eradication of myeloma cellsConsiderations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010Engineered T cells for cancer therapy.Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.Armed and accurate: engineering cytotoxic T cells for eradication of leukemia.Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Adoptive T-cell therapy: adverse events and safety switches.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Clinical applications of gamma delta T cells with multivalent immunity.Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsComparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
P2860
Q24594920-1A063855-7318-4DFD-852D-15324B679D9AQ24632975-6A518A8D-FC62-42AD-BB79-6F5E036A5B11Q24633847-DA85FA61-C8BA-458C-B4D4-510EDB188EEDQ24633960-AFF5E86D-FED2-4483-9111-F4BB45EEB815Q26753082-C9714D7B-2E55-4B58-A5C5-B75895D3DDF0Q26775720-AFE8DF48-DDAE-4A08-9937-D8D96B3E6B11Q26796675-CFDA8A15-CD09-4172-8DA3-50E6D4D891DBQ26826830-536CDA13-3DCE-4D7F-BFB6-4088BB1EAF29Q26830526-0A5643F6-A841-4DAE-B456-002C3952CAD9Q26852919-D9129D78-2D66-4D84-A830-0A3DB393D205Q26866513-F613AD17-8D31-441A-8714-91A0D4058C7DQ27004436-01138C4C-C92E-4C6E-90B5-FBF731631C35Q27006934-1A0C7FD9-2B92-4C04-AEFF-A1B9908F8173Q27013599-B4ECB95D-46D1-4F9F-BB20-976BD9C3F25FQ27312288-F19E16DD-5198-45E4-A561-505530CC1461Q27345402-050E5260-D43B-4B85-AF93-78ADC54895F5Q28533690-E4B71428-43DC-46DD-AE27-0712B65F6A6EQ28553650-782F7206-AE61-44DE-9B3E-C0844477C464Q28727481-0B54DA5B-C713-49D0-BCE2-8E9B3EE4FA5AQ29622949-65BBD7D7-72CF-455A-AC32-33D780A5AE54Q30238693-E93CCBF5-9E76-4E28-8C5E-2006C1B63536Q30535187-C07557F1-CFA3-41A3-B951-932825145080Q30585324-08521173-B83C-462A-A82E-526532E330A6Q33555573-56D85C15-A17F-41E4-B4DF-67A6BC08B030Q33691970-28C5DA82-BCDA-4ED0-9EC4-42BD0A706999Q33766995-5B5A30B4-0E6A-4CAE-892E-B66620C305A9Q33852140-E72AA0F3-CFDE-4B60-87D3-23B769DAF28BQ33992425-C16CE695-335C-4DDA-9A91-A718BDDA0B65Q34025234-2321D0BD-DCC6-4DCB-9034-5D5DA5539CD3Q34080368-E0B3554E-6733-4228-8B69-044C6C95AED9Q34139613-D325CFE8-16E0-4A25-992C-E26AAF654410Q34153598-3C1BD405-D361-415C-8556-88D1FFDDBA9AQ34391263-F0D93188-42CD-460C-BF30-FB0EF4F70339Q34511623-0930E398-538B-4F08-BCA0-B5F4BDBF9DCAQ34557953-8951513B-DA83-4F42-93DF-CB3885C5841DQ34645259-E7127479-1F87-4F82-8819-6DEA56A6F61CQ34677859-75082D9E-22D7-48C6-98DC-87E9A4F003C7Q34760414-CB782D8D-5134-4CDB-B2C4-511D8BCD51A2Q34808631-EF087034-242B-4EF1-9936-26EC3D4E4905Q34876434-ECA1BD0C-07C7-4CB6-915E-F60D3C5C0828
P2860
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@ast
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@en
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@nl
type
label
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@ast
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@en
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@nl
prefLabel
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@ast
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@en
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@nl
P2093
P2860
P1433
P1476
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
@en
P2093
Bipulendu Jena
Gianpietro Dotti
Laurence J N Cooper
P2860
P304
P356
10.1182/BLOOD-2010-01-043737
P407
P577
2010-05-03T00:00:00Z